Cost-effectiveness of sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada
Sodium-glucose cotransporter 2 inhibitors provided more QALYs at a lower price than GLP-1 RA and were cost-effective at current prices. Glucagon-like peptide-1 RA cost-effectiveness may improve if outcomes beyond typical diabetes complications are considered and if generic GLP-1 RA become available.
Authors
- Pedro Marques (ORCID: https://orcid.org/0000-0002-1120-5461)
- Elite Possik (ORCID: https://orcid.org/0000-0003-1578-5819)
- Thomas A. Mavrakanas (ORCID: https://orcid.org/0000-0002-3368-247X)
- Kaberi Dasgupta
- Ethan McNally
- Nisha Gupta
- Michael A. Tsoukas
- W. Alton Russell
- Ankur Pandya
- Abhinav Sharma
Institutions
- McGill University Health Centre (CA)
Publication Details
- Journal
- Canadian Medical Association Journal
- Published
- 2026-02-22
- DOI
- https://doi.org/10.1503/cmaj.250591
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- McGill University
- McGill University Health Centre
- Mitacs